Use of live attenuated influenza vaccines in young children in resource-poor settings  by Isakova-Sivak, Irina
Comment
www.thelancet.com/lancetgh   Vol 4   December 2016 e879
Use of live attenuated inﬂ uenza vaccines in young children 
in resource-poor settings
Children younger than 5 years are in the age group most 
vulnerable to infection with inﬂ uenza virus, and these 
infections contribute substantially to the overall harm 
caused to the general population. Thus, the development 
of safe and eﬃ  cacious vaccines suitable for this age 
group is a high public health priority. The vulnerability of 
young children becomes even more obvious in densely 
populated, low-resource countries with poor health-
care systems and no established inﬂ uenza vaccination 
policies. Much interest has been paid to the performance 
of live attenuated inﬂ uenza vaccines (LAIVs) compared 
with inactivated vaccines in developing countries 
because LAIVs have higher yields during manufacture, the 
puriﬁ cation process is simpler, lot release is quicker, and 
they may be delivered intranasally, removing the need 
for needles. Russian-backbone LAIV has a long history 
of development, and it was a great achievement when 
this technology was licensed to WHO with permission 
to grant sublicenses to vaccine manufacturers in newly 
industrialised and developing countries within the 
framework of the WHO Inﬂ uenza Vaccine Technology 
Transfer Project.1 As a part of this project, the Serum 
Institute of India, Pune, India, adopted the technology, 
and its LAIV is now prequaliﬁ ed by WHO.2
In The Lancet Global Health, two studies are reported by 
W Abdullah Brooks and colleagues3 and John C Victor and 
colleagues4 that present the safety and eﬃ  cacy results 
for an Indian-made Russian-backbone LAIV given to 
young children in Bangladesh and Senegal. Both studies 
were randomised controlled trials, and both conﬁ rmed 
LAIV safety in children aged 2–5 years. Reactions within 
7 days of vaccine receipt were mostly mild, and were 
most commonly cough (6·5% in Bangladesh and 9·7% 
in Senegal) and runny nose (6·1% and 17·1%). This good 
safety proﬁ le is in concordance with the ﬁ ndings in an 
earlier safety and immunogenicity LAIV trial done in 
Bangladesh in 2012.5 Also of note is that Abdullah and 
colleagues’ study in Bangladesh3 included a large cohort 
of children with history of asthma and wheezing, and no 
increase in any safety signals was seen in these children 
following the receipt of the LAIV.
The vaccine eﬃ  cacy diﬀ ered notably between the two 
countries, from 57·5% (95% CI 43·6 to 68·0) in Bangladesh 
to 0·0 % (–26·4 to 20·9) in Senegal, despite use of the 
same LAIV lot. Attack rates for H1N1pdm09 viruses were 
high in both studies, and the absence of vaccine eﬃ  cacy in 
Senegal was mainly due to the lack of protection against 
this strain, which was the predominant vaccine-matched 
strain, and high circulation of mismatched inﬂ uenza B 
strains during the trial. Victor and colleagues4 could ﬁ nd 
no clear explanation for the discrepancy in vaccine eﬃ  cacy 
between study sites. I suggest that the most reasonable 
explanations would be the low temperature stability 
of the H1N1dpm09 LAIV component. The A/California 
strain has 47Glu residue in the haemagglutinin 2 subunit 
that renders the virus unstable.6 Although the shelf life 
and the cold chain of the vaccine had been monitored 
rigorously by the manufacturer, a very hot environment 
in Senegal might have negatively aﬀ ected the infectivity 
of the H1N1dpm09 component. Immunisation in an air-
conditioned environment might help to maintain virus 
infectivity.
Another possibility for the diﬀ erences in results could 
be the baseline immune statuses of the participants. 
Unfortunately, no immunogenicity testing was done in 
either trial, but the national surveillance data suggest 
that H1N1 viruses circulated widely in Bangladesh in the 
year before the study, whereas in Senegal these viruses 
had been detected rarely between 2010 and the time of 
the LAIV trial. Children in the Bangladesh study, unlike 
those in the Senegal study, therefore, might have had 
some degree of pre-existing immunity to H1N1 viruses 
that was boosted by the LAIV. The use of a two-dose 
schedule might have been more eﬃ  cacious in Senegal, 
therefore, and should be further considered as a possible 
option for immunising young children who have no pre-
existing inﬂ uenza immunity there and elsewhere.
The studies by Brooks and colleagues3 and Victor and 
colleagues4 have more than local relevance because of 
the concerns about poor results from observational 
studies of annual eﬀ ectiveness assessments of Ann-
Arbor-backbone LAIV. Because of these results, in June 
2016, the US Advisory Committee on Immunization 
Practices withdrew its preferential recommendation 
for the use of LAIV in children.7 Of note, though, other 
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eﬃ  cacy with the same LAIV formulation in the same 
inﬂ uenza season8–10 and, therefore, these countries 
continue to recommend LAIV for children.
The important work of Brooks and colleagues and 
Victor and colleagues will deﬁ nitely contribute to the 
global conversation about the need to better understand 
the performance of LAIVs in resource-poor settings 
with high population densities. Work should proceed 
with assessments of the eﬀ ects of LAIVs on inﬂ uenza 
morbidity and mortality in children younger than 2 years, 
for whom the burden of severe disease due to inﬂ uenza 
virus infection is highest in low-income countries.
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At the end of the Bangladesh study, my laboratory was asked by the study 
sponsor (PATH) to test the masked inﬂ uenza-positive specimens for wild-type 
or vaccine-type virus. I did not participate in the study design, study conduct, 
or data analysis. 
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